Researcher
Lisa Moris
- Disciplines:Andrology, Cancer biology, Urology and nephrology not elsewhere classified
Affiliations
- Department of Cellular and Molecular Medicine (Department)
Member
From2 Aug 2020 → Today - Laboratory of Molecular Endocrinology (Division)
Member
From1 Aug 2016 → 31 Dec 2019
Projects
1 - 1 of 1
- Clinical and preclinical studies of modulators of high-risk prostate cancer with metastatic potentialFrom1 Aug 2016 → 29 Apr 2022Funding: Private funding of national origin - undefined, BOF - doctoral mandates
Publications
1 - 10 of 51
- Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium.(2022)
Authors: Lisa Moris
Pages: 503 - 514 - Clinical and preclinical studies of modulators of high-risk prostate cancer with metastatic potential(2022)
Authors: Lisa Moris, Frank Claessens, Steven Joniau
- Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.(2022)
Authors: Lisa Moris
Pages: 337 - 346 - Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer(2022)
Authors: Lisa Moris, Diether Lambrechts, Christine Helsen, Bart Ghesquière, Stefaan Soenen, Roy Eerlings, Sarah El Kharraz, Hendrik Van Poppel, Steven Joniau, Frank Claessens
Pages: 527 - 541Number of pages: 15 - Diagnostic and prognostic factors in patients with prostate cancer: a systematic review(2022)
Authors: Lisa Moris
Number of pages: 10 - Small-molecule profiling for steroid receptor activity using a universal steroid receptor reporter assay(2021)
Authors: Roy Eerlings, Truong Tien Nguyen, Elien Smeets, Lisa Moris, Sarah El Kharraz, Arnout Voet, Wim Dehaen, Frank Claessens, Christine Helsen
Number of pages: 12 - The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer(2021)
Authors: Lisa Moris
Pages: 943 - 946Number of pages: 4 - The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation.(2021)
Authors: Sarah El Kharraz, Vanessa Dubois, Truong Tien Nguyen, Arnout Voet, Roy Eerlings, Stefan Prekovic, Elien Smeets, Lisa Moris, Kevin Verstrepen, Gertrudis Carmeliet, et al.
Pages: 1 - 19Number of pages: 19 - Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer(2021)
Authors: Gaëtan Devos, Gert De Meerleer, Marcella Baldewijns, Lisa Moris, Hendrik Van Poppel, Charlien Berghen, Wouter Everaerts, Frank Claessens, Steven Joniau
Pages: 739 - 762Number of pages: 24 - Evaluation of oncological outcomes and data quality in studies assessing nerve sparing versus non-nerve sparing radical prostatectomy in non-metastatic prostate cancer: A systematic review(2021)
Authors: Lisa Moris, G Gandaglia, A Vilaseca, T Van den Broeck, E Briers, M De Santis, S Gillessen, N Grivas, A Henry, TB Lam, et al.
Pages: S426 - S427Number of pages: 2